Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Payables (2020 - 2026)

Unicycive Therapeutics filings provide 4 years of Payables readings, the most recent being $1.1 million for Q4 2024.

  • On a quarterly basis, Payables fell 47.1% to $1.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.1 million, a 47.1% decrease, with the full-year FY2024 number at $1.1 million, down 47.1% from a year prior.
  • Payables hit $1.1 million in Q4 2024 for Unicycive Therapeutics, up from $519000.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $2.0 million in Q4 2023 to a low of $503000.0 in Q2 2023.
  • Median Payables over the past 4 years was $800000.0 (2022), compared with a mean of $945923.1.
  • The widest YoY moves for Payables: up 192.84% in 2024, down 47.58% in 2024.
  • Unicycive Therapeutics' Payables stood at $742000.0 in 2021, then grew by 14.02% to $846000.0 in 2022, then soared by 136.41% to $2.0 million in 2023, then crashed by 47.1% to $1.1 million in 2024.
  • The last three reported values for Payables were $1.1 million (Q4 2024), $519000.0 (Q3 2024), and $1.5 million (Q2 2024) per Business Quant data.